> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bristol Myers Cuts 2026 EPS Outlook To $6.35-$6.55 Even As It Lifts Revenue Guidance
- URL: https://www.bullished.co/bristol-myers-cuts-2026-eps-outlook-to-6-35-6-55-even-as-it-lifts-revenue-guidance-5d018861/
- Published: 2026-10-29T15:26:34.000Z
- Updated: 2026-10-29T15:26:34.000Z
- Description: Deal charges of $1,558 million swamped third-quarter earnings, pulling adjusted EPS down to $1.35 from $1.63 on 7% revenue growth.
- Author: Matteo Parrino
- Tags: Earnings, BMY, Industry: Healthcare

Bristol Myers Squibb raised its 2026 revenue forecast but cut its adjusted earnings-per-share outlook to $6.35-$6.55 from $6.75-$7.00, as [$1,558 million in third-quarter charges](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000024/bmy-20260930.htm?ref=bullished.co) for licensing deals on unapproved drugs more than doubled the year-earlier $633 million, according to the company's 10-Q filed Thursday.

## Revenue up, earnings guidance down

Bristol Myers, the drugmaker behind the cancer drugs Opdivo and Yervoy and the blood thinner Eliquis, now expects full-year revenue of about $49.75 billion to $50.25 billion, up from $49.0 billion to $50.0 billion in July, according to its [earnings release](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000022/a2026q3ex991-filing.htm?ref=bullished.co).

The EPS cut traces to one line. The guidance now includes a $(0.60) per-share hit from acquired in-process research and development (IPRD, the cost of licensing unfinished drugs) and licensing income, against $(0.02) in July.

Third-quarter adjusted EPS [fell to $1.35](https://wtop.com/national/2026/10/bristol-myers-q3-earnings-snapshot/?ref=bullished.co) from $1.63 even as revenue rose 7% to $13,069 million. The 10-Q blames the higher IPRD charges and the end of royalty income on diabetes products; that income was $286 million in the year-earlier quarter.

## Three deals drove the charge

The charges were led by $775 million to Hengrui, $500 million to BioNTech and $250 million in SystImmune milestones. Hengrui's was an upfront fee plus an anniversary payment under licenses for 13 early-stage assets; BioNTech's was the first anniversary payment on its pumitamig collaboration.

The [second-quarter 10-Q](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000020/bmy-20260630.htm?ref=bullished.co) showed $94 million of IPRD for six months and none in that quarter, so nearly all of the $1,651 million nine-month total landed in the third quarter. The SystImmune milestone is payable in the fourth quarter of 2026.

## Newer drugs fill the patent gap

Pomalyst sales fell to $130 million from $675 million and Revlimid to $303 million from $575 million as generics arrived. Eliquis rose 25% to $4,690 million, helped by lower rebates after a U.S. list price cut. The growth portfolio, including Breyanzi, Camzyos and Reblozyl, rose 12% to $7,662 million.

Management expects about $2.0 billion in annual savings by the end of 2027\. Nine-month operating cash flow fell to $8,678 million from $12,182 million, and dividends of $0.63 per share totaled $1,288 million declared in the quarter.

The FDA's target decision date for mezigdomide, Bristol Myers' multiple myeloma drug, is May 13, 2027.

### Sources

- [10-Q Filing — Bristol-Myers Squibb (BMY)](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000024/bmy-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Bristol-Myers Squibb (BMY), Q2 FY2026 filed 2026-07-30 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000020/bmy-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, a2026q3ex991-filing.htm) — Bristol-Myers Squibb, filed 2026-10-29](https://www.sec.gov/Archives/edgar/data/0000014272/000001427226000022/a2026q3ex991-filing.htm?ref=bullished.co) — SEC EDGAR
- [Bristol Myers: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/bristol-myers-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings](https://finance.yahoo.com/markets/stocks/articles/heres-key-metrics-tell-us-123005235.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Bristol-Myers Squibb Company Non-GAAP EPS of $1.35 beats by $0.13, revenue of $13.1B beats](https://seekingalpha.com/news/4660049-bristol-myers-squibb-company-non-gaap-eps-of-135-beats-by-013-revenue-of-131b-beats-by-370m-raises-fy-guidance?ref=bullished.co) — seekingalpha.com
- [Bristol Myers Squibb (BMY) Stock Fair Value Edges Lower On Split Analyst Views](https://uk.finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-231905211.html?ref=bullished.co) — Yahoo Finance
- [Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates](https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-bmy-q3-113504106.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on Bristol-Myers Squibb

- [Bristol Myers CEO Hedges On How Much Milvexian AFib Data Its First Press Release Will Show](https://www.bullished.co/bristol-myers-ceo-hedges-on-how-much-milvexian-afib-data-its-first-press-release-will-show-4d4b3134/)
- [Bristol Myers Execs Concede Cobenfi Needs Faster Starts, Explain Admilpirant's 120 mg Miss](https://www.bullished.co/bristol-myers-execs-concede-cobenfi-needs-faster-starts-explain-admilpirants-120-mg-miss-ba53ed99/)
- [Bristol Myers Lifts Sales Outlook To About $49.75 Billion-$50.25 Billion, Trims EPS Guidance On $0.60 Research Charge](https://www.bullished.co/bristol-myers-lifts-sales-outlook-to-about-49-75-billion-50-25-billion-trims-eps-guidance-f30aef90/)

[All Bristol-Myers Squibb (BMY) coverage →](https://www.bullished.co/tag/bmy/)